Related Experiment Videos
A Critical Evaluation of sst3 and sst5 Immunohistochemistry in Human Pituitary Adenomas
Background:
Somatostatin receptor (sst) overexpression in neuroendocrine tumors allows sst-targeted tumor imaging and therapy with long-acting, cold, or radioactive somatostatin analogs. sst2 has been most important, owing to its wide overexpression and high affinity for somatostatin analogs, but other sst subtypes become of increasing clinical interest due to drug development. Immunohistochemistry is the preferred method to detect sst in resected tumor tissues. While it is established for sst2 using the antibody UMB-1, there is less experience for other sst subtypes.
Methods:
sst3 and sst5 immunohistochemistry using the antibodies UMB-5 and UMB-4 was evaluated in 60 pituitary adenomas and compared with in vitro sst autoradiography (ARG), the in vitro gold standard method to assess sst.
Results:
UMB-4 immunohistochemistry for sst5 yielded membranous staining of tumor cells. It correlated fairly well with ARG, results matching in 80% of tumors. UMB-5 immunohistochemistry for sst3 showed not only a membranous, but also cytoplasmic background staining. Agreement with ARG was limited. All tumors showed UMB-5 staining, while only 57% were positive by ARG. In comparison, UMB-1 staining levels showed a highly significant correlation with autoradiographic sst2 density levels (R2 = 0.797). Not only tumor cells, but also intratumoral blood vessels were immunohistochemically positive for sst2, 3, and 5.
Conclusion:
UMB-1 immunohistochemistry for sst2 is excellent. sst3 immunohistochemistry using UMB-5 is not yet optimal, with suspected limited specificity, and should be applied with caution. UMB-4 immunohistochemistry for sst5 appears to be equivalent to sst5-ARG and suitable for diagnostic applications.
Insights
Immunohistochemistry for somatostatin receptors (sst) in neuroendocrine tumors shows UMB-4 for sst5 is reliable, but UMB-5 for sst3 needs caution. UMB-1 for sst2 remains excellent for tumor diagnostics.
Area of Science:
- Oncology
- Endocrinology
- Pathology
Background:
- Somatostatin receptor (sst) overexpression in neuroendocrine tumors (NETs) is crucial for targeted imaging and therapy.
- While sst2 is well-established, other sst subtypes are gaining clinical importance due to novel drug development.
- Immunohistochemistry (IHC) is the primary method for detecting sst in resected tumor tissues.
Purpose of the Study:
- To evaluate the diagnostic utility of UMB-5 and UMB-4 antibodies for sst3 and sst5 immunohistochemistry in pituitary adenomas.
- To compare IHC results with in vitro sst autoradiography (ARG), the gold standard for sst assessment.
- To assess the reliability of different sst antibodies for clinical applications in NETs.
Main Methods:
- Sixty pituitary adenomas were analyzed using sst3 and sst5 immunohistochemistry with UMB-5 and UMB-4 antibodies, respectively.
- Results were compared against in vitro sst autoradiography (ARG) as the gold standard.
- sst2 IHC using UMB-1 was also assessed for correlation with ARG.
Main Results:
- UMB-4 IHC for sst5 showed good correlation (80%) with ARG and detected membranous staining.
- UMB-5 IHC for sst3 exhibited limited agreement with ARG (57% positive by ARG vs. 100% by IHC) and showed cytoplasmic background staining.
- UMB-1 IHC for sst2 demonstrated a highly significant correlation (R² = 0.797) with ARG, and positivity was observed in tumor cells and blood vessels.
Conclusions:
- UMB-1 IHC for sst2 is an excellent method for clinical use.
- UMB-4 IHC for sst5 is suitable for diagnostic applications, showing equivalence to sst5-ARG.
- UMB-5 IHC for sst3 requires cautious application due to suspected limited specificity and suboptimal performance compared to ARG.